Last reviewed · How we verify
bevacizumab, Paclitaxel
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while paclitaxel is a microtubule inhibitor that blocks cell division.
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while paclitaxel is a microtubule inhibitor that blocks cell division. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic colorectal cancer.
At a glance
| Generic name | bevacizumab, Paclitaxel |
|---|---|
| Also known as | Avastin |
| Sponsor | Swiss Cancer Institute |
| Drug class | Antiangiogenic agent, Microtubule inhibitor |
| Target | VEGF-A, Tubulin |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thereby inhibiting the formation of new blood vessels that tumors need to grow. Paclitaxel, on the other hand, stabilizes microtubules, preventing cell division and leading to cell death. This combination of mechanisms makes bevacizumab and paclitaxel a powerful treatment for certain types of cancer.
Approved indications
- Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic colorectal cancer
Common side effects
- Hypertension
- Neutropenia
- Fatigue
- Asthenia
- Diarrhea
- Abdominal pain
- Nausea
- Vomiting
- Dyspnea
- Cough
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (PHASE1)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bevacizumab, Paclitaxel CI brief — competitive landscape report
- bevacizumab, Paclitaxel updates RSS · CI watch RSS
- Swiss Cancer Institute portfolio CI